DUBLIN–(BUSINESS WIRE)–Feb 4, 2021–
The "Vestibular Schwannoma – Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Vestibular Schwannoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Unilateral/asymmetric hearing loss and/or tinnitus and loss of balance/dizziness are early signs of a vestibular schwannoma. Unfortunately, early detection of the tumor is sometimes difficult because the symptoms may be subtle and may not appear in the beginning stages of growth. Once the symptoms appear, a thorough ear examination and hearing and balance testing (audiogram, electronystagmography, and auditory brainstem responses) are essential for proper diagnosis. Magnetic resonance imaging (MRI) scans are critical in the early detection of a vestibular schwannoma and are helpful in determining the location and size of a tumor and in planning its microsurgical removal.
There are three options for managing a vestibular schwannoma: (1) surgical removal, (2) radiation, and (3) observation. Sometimes, the tumor is surgically removed (excised). The exact type of operation done depends on the size of the tumor and the level of hearing in the affected ear. If the tumor is small, hearing may be saved and accompanying symptoms may improve by removing it to prevent its eventual effect on the hearing nerve. As the tumor grows larger, surgical removal is more complicated because the tumor may have damaged the nerves that control facial movement, hearing, and balance and may also have affected other nerves and structures of the brain. As an alternative to conventional surgical techniques, radiosurgery (that is, radiation therapy – the "gamma knife" or LINAC) may be used to reduce the size or limit the growth of the tumor. Radiation therapy is sometimes the preferred option for elderly patients, patients in poor medical health, patients with bilateral vestibular schwannoma (tumor affecting both ears), or patients whose tumor is affecting their only hearing ear.
Vestibular Schwannoma Emerging Drugs Chapters
This segment of the Vestibular Schwannoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vestibular Schwannoma Emerging Drugs
Selumetinib is being developed by AstraZeneca for the treatment of vestibular schwannoma and is currently in Phase 2 trial of clinical study. It acts MAP Kinase 1 inhibitors and MAP Kinase 2 inhibitors. The Phase 2 trial got initiated in May 2017 and is expected to get completed by May 2022 with estimated 34 enrolled participants.
Vestibular Schwannoma: Therapeutic Assessment
This segment of the report provides insights about the different Vestibular Schwannoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Vestibular Schwannoma
There are approx. 10+ key companies which are developing the therapies for Vestibular Schwannoma. The companies which have their Vestibular Schwannoma drug candidates in the most advanced stage, i. e. phase II include, AstraZeneca.
This report covers around 10+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Vestibular Schwannoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Vestibular Schwannoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vestibular Schwannoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vestibular Schwannoma drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Vestibular Schwannoma R&D. The therapies under development are focused on novel approaches to treat/improve Vestibular Schwannoma.
Vestibular Schwannoma Report Insights
- Vestibular Schwannoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Vestibular Schwannoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Vestibular Schwannoma drugs?
- How many Vestibular Schwannoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vestibular Schwannoma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vestibular Schwannoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vestibular Schwannoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Recursion Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8enmkv
View source version on businesswire.com:https://www.businesswire.com/news/home/20210204005699/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 02/04/2021 08:56 AM/DISC: 02/04/2021 08:56 AM